About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Investors
Corporate Presentation
Financial Calendar
Regulated Information
SEC Filings
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
R&D Day
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Scientific Clinical | Nanobiotix’s partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia
Corporate | Nanobiotix Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations
3 October 2016
Scientific Clinical | Nanobiotix presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer
14 November 2016
Scientific Clinical | Nanobiotix’s partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia
Published by
adminvl
on
20 October 2016
No translations available for this page
